Ovid Therapeutics (OVID) News Today $0.43 -0.01 (-3.17%) Closing price 04:00 PM EasternExtended Trading$0.45 +0.02 (+4.60%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Ovid Therapeutics price target lowered to $2 from $3 at H.C. WainwrightMarch 25 at 2:23 AM | markets.businessinsider.comOvid Therapeutics price target lowered to $4 from $5 at BTIGMarch 25 at 2:23 AM | markets.businessinsider.comBTIG Research Issues Pessimistic Forecast for Ovid Therapeutics (NASDAQ:OVID) Stock PriceMarch 25 at 1:48 AM | americanbankingnews.comQ1 EPS Forecast for Ovid Therapeutics Raised by AnalystMarch 17, 2025 | americanbankingnews.comQ2 EPS Estimates for Ovid Therapeutics Cut by William BlairMarch 16, 2025 | americanbankingnews.comWhat is Wedbush's Estimate for OVID FY2029 Earnings?March 15, 2025 | americanbankingnews.comEquities Analysts Set Expectations for OVID Q1 EarningsMarch 15, 2025 | americanbankingnews.comOvid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 12, 2025 | finance.yahoo.comWilliam Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)March 12, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $3 from $4 at WedbushMarch 12, 2025 | markets.businessinsider.comWe're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn RateMarch 11, 2025 | uk.finance.yahoo.comOvid Therapeutics sees cash runway into 2H26March 11, 2025 | markets.businessinsider.comOvid Therapeutics reports Q4 EPS (13c), consensus (17c)March 11, 2025 | markets.businessinsider.comOvid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comOvid Therapeutics appoints new board member and updates compensation policyMarch 7, 2025 | investing.comOvid Therapeutics appoints Papadopoulos to board of directorsMarch 4, 2025 | markets.businessinsider.comOvid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of DirectorsMarch 3, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Vertex Pharmaceuticals (VRTX) and Viridian Therapeutics (VRDN)February 27, 2025 | markets.businessinsider.comOvid Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comOvid Therapeutics faces Nasdaq delisting over share priceFebruary 13, 2025 | msn.comOvid stock plunges to 52-week low, touches $0.59 amid downturnFebruary 12, 2025 | msn.comOvid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comOvid Therapeutics stock hits 52-week low at $0.68 amid downturnJanuary 31, 2025 | msn.comOppenheimer raises Ovid stock rating, sets $4 price targetJanuary 31, 2025 | msn.comOvid therapeutics president and COO acquires $4,971 in stockJanuary 30, 2025 | msn.comOvid Therapeutics upgraded to Outperform from Perform at OppenheimerJanuary 30, 2025 | markets.businessinsider.comOvid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’January 30, 2025 | markets.businessinsider.comOppenheimer Upgrades Ovid Therapeutics (OVID)January 30, 2025 | msn.comOppenheimer Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Outperform"Oppenheimer upgraded Ovid Therapeutics from a "market perform" rating to an "outperform" rating and set a $4.00 target price for the company in a research note on Wednesday.January 29, 2025 | marketbeat.comOvid Therapeutics Insider Ups Holding During YearJanuary 23, 2025 | finance.yahoo.comShort Interest in Ovid Therapeutics Inc. (NASDAQ:OVID) Decreases By 27.0%Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 692,000 shares, a decrease of 27.0% from the December 15th total of 947,800 shares. Based on an average daily volume of 251,900 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.2% of the shares of the stock are short sold.January 16, 2025 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, four have given a buy rJanuary 12, 2025 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Sees Significant Growth in Short InterestOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 947,800 shares, a growth of 28.0% from the November 30th total of 740,300 shares. Based on an average daily trading volume, of 212,600 shares, the days-to-cover ratio is currently 4.5 days. Currently, 1.7% of the company's shares are short sold.December 31, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by BrokeragesOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has gDecember 18, 2024 | marketbeat.comBiohaven Ltd.’s Promising Pipeline and Strategic Partnerships Drive Buy RecommendationDecember 17, 2024 | markets.businessinsider.comConvergent Therapeutics Appoints Barbara Duncan to Board of DirectorsDecember 11, 2024 | finance.yahoo.comOvid Therapeutics’ OV329: Promising Safety and Efficacy Lead to Buy RatingDecember 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Ovid Therapeutics (OVID)December 9, 2024 | markets.businessinsider.comHC Wainwright Has Positive Outlook of OVID FY2024 EarningsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Stock analysts at HC Wainwright raised their FY2024 earnings per share estimates for Ovid Therapeutics in a research report issued to clients and investors on Wednesday, December 4th. HC Wainwright analyst R. Selvaraju now anticipates that theDecember 6, 2024 | marketbeat.comOvid Therapeutics’ KCC2 Activators Show Promise for Excitability Disorders: Analyst Recommends Buy with $3 Price TargetDecember 6, 2024 | markets.businessinsider.comOvid to present posters on pipeline program for neuronal hyperexcitabilityDecember 3, 2024 | markets.businessinsider.comOvid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Rating of "Moderate Buy" from AnalystsOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, four have issued a buy rating and oneNovember 23, 2024 | marketbeat.comOvid Therapeutics IncNovember 20, 2024 | morningstar.comB. Riley Decreases Earnings Estimates for Ovid TherapeuticsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Investment analysts at B. Riley cut their FY2024 EPS estimates for shares of Ovid Therapeutics in a research report issued on Monday, November 18th. B. Riley analyst K. Patel now anticipates that the company will earn ($0.39) per share for theNovember 20, 2024 | marketbeat.comOppenheimer Reaffirms Their Hold Rating on Ovid Therapeutics (OVID)November 15, 2024 | markets.businessinsider.comOvid Therapeutics (OVID) Gets a Buy from WedbushNovember 15, 2024 | markets.businessinsider.comWedbush Predicts Lower Earnings for Ovid TherapeuticsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Investment analysts at Wedbush decreased their FY2024 EPS estimates for shares of Ovid Therapeutics in a report issued on Wednesday, November 13th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.39) per share for the yeNovember 15, 2024 | marketbeat.comWilliam Blair Predicts Higher Earnings for Ovid TherapeuticsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at William Blair boosted their FY2024 earnings per share estimates for Ovid Therapeutics in a research report issued on Tuesday, November 12th. William Blair analyst S. Schram now anticipates that the company will posNovember 15, 2024 | marketbeat.comWilliam Blair Issues Positive Estimate for OVID EarningsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at William Blair increased their Q2 2025 earnings estimates for Ovid Therapeutics in a note issued to investors on Tuesday, November 12th. William Blair analyst S. Schram now anticipates that the company will post earNovember 14, 2024 | marketbeat.comOvid Therapeutics: Strategic Developments and Financial Stability Lead to Buy RatingNovember 14, 2024 | markets.businessinsider.com Remove Ads Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address OVID Media Mentions By Week OVID Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OVID News Sentiment▼-0.050.68▲Average Medical News Sentiment OVID News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OVID Articles This Week▼62▲OVID Articles Average Week Remove Ads Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MCRB News MGNX News VIRI News FTLF News VXRT News EDIT News ELUT News RENB News TLSA News ADVM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OVID) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
